7 April 2025 - Pfizer Korea has won national reimbursement for its oral JAK inhibitor Xeljanz (tofacitinib), expanding access to children with hard to treat juvenile arthritis as of last Tuesday.

The new coverage, announced by the Ministry of Health and Welfare on 25 March, applies to paediatric patients aged two to 17 with polyarticular course juvenile idiopathic arthritis, extended oligoarticular juvenile idiopathic arthritis or juvenile psoriatic arthritis—but only after at least one biologic drug has failed or caused serious side effects.

Read Korea Biomedical Review article